Singapore markets close in 3 hours 37 minutes
  • Straits Times Index

    3,224.36
    -16.22 (-0.50%)
     
  • Nikkei

    26,883.66
    +144.63 (+0.54%)
     
  • Hang Seng

    20,333.74
    -383.50 (-1.85%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • BTC-USD

    30,141.81
    +819.09 (+2.79%)
     
  • CMC Crypto 200

    673.43
    +0.05 (+0.01%)
     
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • Dow

    31,261.90
    +8.80 (+0.03%)
     
  • Nasdaq

    11,354.62
    -33.88 (-0.30%)
     
  • Gold

    1,853.60
    +11.50 (+0.62%)
     
  • Crude Oil

    110.81
    +0.53 (+0.48%)
     
  • 10-Yr Bond

    2.7870
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,551.43
    +2.31 (+0.15%)
     
  • Jakarta Composite Index

    6,841.70
    -76.44 (-1.10%)
     
  • PSE Index

    6,710.64
    -35.69 (-0.53%)
     

Galera Therapeutics Surges After Corrected Trial Data

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Sam Boughedda

Investing.com — Galera Therapeutics Inc (NASDAQ:GRTX) shares jumped more than 144% in early Tuesday trading on the back of amended statistical significance data from its phase 3 trial of its drug to treat those undergoing radiation therapy.

The trial assessed the drug, avasopasem, in treating radiotherapy-induced tissue swelling in the mouth in patients with locally advanced head and neck cancer. The corrected data means the phase 3 trial achieved statistical significance on the primary endpoint of reduction in the incidence of this condition

The FDA has granted avasopasem with Breakthrough Therapy Designation (BTD) for the reduction swelling in the mouth induced by radiotherapy.

Galera had previously announced data that showed statistical significance on the primary endpoint was not achieved.

The company cited an error by the contract research organization. "Correction of this error resulted in improved p-values for the primary and secondary endpoints."

Related Articles

Galera Therapeutics Surges After Corrected Trial Data

Uber looking to sell Didi, other non-strategic stakes -CEO says

European shares fall again with cenbank meetings in focus

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting